Pharma · Public company · Wilmington, DE, US

Incyte Corp

Ticker INCY · SEC CIK 0000879169

Track this companyFree. Adds Incyte Corp to your Dealase workspace and tells you when its record changes.

Clinical trials2525 recruiting or active

Pipeline programs29From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline29

Best Available TreatmentPhase 3 · Essential ThrombocythemiaClinicalTrials.gov · fetched Nov 12, 2026
BevacizumabPhase 3 · CRC (Colorectal Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
CorticosteroidsPhase 3 · Chronic Graft-versus-host-diseaseClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 3 · Graft-versus-host Disease (GVHD)ClinicalTrials.gov · fetched Nov 12, 2026
FOLFOXPhase 3 · CRC (Colorectal Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
INCA033989Phase 3 · Essential ThrombocythemiaClinicalTrials.gov · fetched Nov 12, 2026
INCA034176Phase 3 · Chronic Graft-versus-host-diseaseClinicalTrials.gov · fetched Nov 12, 2026
INCA33890Phase 3 · CRC (Colorectal Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
INCB123667Phase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
INCB161734Phase 3 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Investigator's choice of chemotherapyPhase 3 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Investigator's choice of chemotherapyPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
Methotrexate (MTX)Phase 3 · Graft-versus-host Disease (GVHD)ClinicalTrials.gov · fetched Nov 12, 2026
Mycophenolate mofetil (MMF)Phase 3 · Graft-versus-host Disease (GVHD)ClinicalTrials.gov · fetched Nov 12, 2026
povorcitinibPhase 3 · Hidradenitis Suppurativa (HS)ClinicalTrials.gov · fetched Nov 12, 2026
Ruxolitinib (Rux)Phase 3 · Graft-versus-host Disease (GVHD)ClinicalTrials.gov · fetched Nov 12, 2026
Ruxolitinib CreamPhase 3 · Hidradenitis SuppurativaClinicalTrials.gov · fetched Nov 12, 2026
Tacrolimus (Tac)Phase 3 · Graft-versus-host Disease (GVHD)ClinicalTrials.gov · fetched Nov 12, 2026
Vehicle CreamPhase 3 · Hidradenitis SuppurativaClinicalTrials.gov · fetched Nov 12, 2026
AxatilimabPhase 2 · Chronic Graft-versus-host-diseaseClinicalTrials.gov · fetched Nov 12, 2026
Best available Treatment (BAT)Phase 2 · Chronic Graft-versus-host-diseaseClinicalTrials.gov · fetched Nov 12, 2026
INCA000585Phase 2 · Immune ThrombocytopeniaClinicalTrials.gov · fetched Nov 12, 2026
INCB000928Phase 2 · Fibrodysplasia Ossificans Progressiva (FOP)ClinicalTrials.gov · fetched Nov 12, 2026
RuxolitinibPhase 2 · Chronic Graft-versus-host-diseaseClinicalTrials.gov · fetched Nov 12, 2026
Bioavailability enhancerPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
INCA033989Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
INCA036873Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
INCA036978Phase 1 · Myeloproliferative NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
Standard disease-directed therapyPhase 1 · Myeloproliferative NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AMLPHASE1 · NOT_YET_RECRUITING · started Jan 31, 2027ClinicalTrials.gov NCT07511062 · fetched Nov 12, 2026
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular LymphomaPHASE2 · RECRUITING · started Oct 9, 2026ClinicalTrials.gov NCT07731789 · fetched Nov 12, 2026
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaPHASE3 · RECRUITING · started Sep 8, 2026ClinicalTrials.gov NCT07623200 · fetched Nov 12, 2026
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)PHASE2 · RECRUITING · started May 20, 2026ClinicalTrials.gov NCT07124078 · fetched Nov 12, 2026
Study of INCA036978 in Participants With Myeloproliferative NeoplasmsPHASE1 · RECRUITING · started May 11, 2026ClinicalTrials.gov NCT07441694 · fetched Nov 12, 2026
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaPHASE3 · RECRUITING · started Apr 9, 2026ClinicalTrials.gov NCT07522073 · fetched Nov 12, 2026
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult ParticipantsPHASE1 · ACTIVE_NOT_RECRUITING · started Mar 19, 2026ClinicalTrials.gov NCT07448155 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerPHASE3 · RECRUITING · started Mar 5, 2026ClinicalTrials.gov NCT07284849 · fetched Nov 12, 2026
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaPHASE2 · RECRUITING · started Feb 12, 2026ClinicalTrials.gov NCT07356245 · fetched Nov 12, 2026
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesPHASE2 · RECRUITING · started Feb 4, 2026ClinicalTrials.gov NCT07228624 · fetched Nov 12, 2026
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaPHASE2 · RECRUITING · started Feb 2, 2026ClinicalTrials.gov NCT07213973 · fetched Nov 12, 2026
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesPHASE1 · RECRUITING · started Jan 8, 2026ClinicalTrials.gov NCT07195916 · fetched Nov 12, 2026
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersPHASE2 · RECRUITING · started Dec 29, 2025ClinicalTrials.gov NCT07104565 · fetched Nov 12, 2026
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPHASE3 · RECRUITING · started Dec 9, 2025ClinicalTrials.gov NCT07214779 · fetched Nov 12, 2026
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaPHASE1 · RECRUITING · started Nov 3, 2025ClinicalTrials.gov NCT07049575 · fetched Nov 12, 2026
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)PHASE3 · ACTIVE_NOT_RECRUITING · started Jun 12, 2025ClinicalTrials.gov NCT06958211 · fetched Nov 12, 2026
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)PHASE3 · RECRUITING · started Apr 2, 2025ClinicalTrials.gov NCT06615050 · fetched Nov 12, 2026
Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibPHASE3 · RECRUITING · started Feb 28, 2025ClinicalTrials.gov NCT06855498 · fetched Nov 12, 2026
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseasePHASE3 · RECRUITING · started Jan 21, 2025ClinicalTrials.gov NCT06585774 · fetched Nov 12, 2026
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseasePHASE2 · ACTIVE_NOT_RECRUITING · started Oct 11, 2024ClinicalTrials.gov NCT06388564 · fetched Nov 12, 2026
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic LeukemiaPHASE1_PHASE2 · RECRUITING · started Aug 2, 2024ClinicalTrials.gov NCT06523556 · fetched Nov 12, 2026
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaPHASE2 · RECRUITING · started May 5, 2022ClinicalTrials.gov NCT05090891 · fetched Nov 12, 2026
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)PHASE1_PHASE2 · RECRUITING · started Nov 24, 2021ClinicalTrials.gov NCT04061421 · fetched Nov 12, 2026
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)PHASE2 · RECRUITING · started Jun 20, 2020ClinicalTrials.gov NCT04374305 · fetched Nov 12, 2026
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaPHASE1_PHASE2 · RECRUITING · started Sep 13, 2018ClinicalTrials.gov NCT03681561 · fetched Nov 12, 2026

SEC filings12

10-Q · 10-QSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 31, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Jul 28, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 28, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 6, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 22, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 9, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 8, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Apr 28, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 28, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Mar 30, 2026 · fetched Nov 12, 2026